Not an actual patient with Fabry disease.
Not an actual patient with Fabry disease.

Identify amenable GLA variants

You can also determine whether your patient's GLA variant is amenable by:

The Galafold Full Prescribing Information includes a list of GLA variants that have been identified as amenable to Galafold.

For answers to questions about amenability, you can also contact Amicus Medical Information at
1-877-4-AMICUS or


Galafold® (migalastat) is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Help your patients determine if their GLA variant is amenable to Galafold

Learn more about Fabry disease at

Understand more about the complexities of this disease, including signs, symptoms, how diagnosis can vary between genders, and much more.

Visit Now
Download the Galafold Patient Referral Form

This form serves a dual purpose:
as a prescription for Galafold and as a way for patients to register for AMICUS ASSIST®.